deficiency and bone disease. Thus, we have identified
), insulin-like DBP (Yang et al., 1990) . DBP was present exclusively growth factor-II receptor, or ecto-5Ј-nucleotidase (not in urine from megalin-deficient but not control animals shown). However, electron microscopical analysis dem-( Figure 2B ). onstrated that components of the endocytic apparatus, including endosomes, lysosomes, and recycling vesicles (dense apical tubules) were significantly reduced Megalin Is the Renal DBP Receptor To test directly whether megalin binds DBP, the carrier in number (Willnow et al., 1996) . This result suggested a deficiency in the uptake of filtered macromolecules in was purified from human serum and from urine of patients with Fanconi syndrome, who are known to excrete proximal tubules lacking megalin ( Figure 1E ). To test this 
125
I-labeled DBP was infused directly into the renal arteries of rats, and the uptake of radioactivity in kidney, blood, and urine was determined (see Experimental Procedures). Sixty minutes after infusion, 86.5% of the radioactivity was found in the circulation as proteolytic degradation products (Table 2 ). In contrast, when megalin activity was blocked by coinjection of RAP, only 13.4% of Figures 7C and 7D) . The lack of continuity of tubules. In the presence of RAP, the filtered precursor the bone surfaces in the knockout mice was most likely molecules were lost in the urine and only nonfiltered a consequence of perforating osteoclastic resorptions metabolites were available for conversion ( Table 2) . As occurring in high bone turnover conditions. Finally, disdepicted in Figure 5B Complete cloning and sequencing of rat gp330/"megalin." A distinctive member of the low density lipoprotein receptor gene family.
